eicosapentaenoic acid / COX2 Cancer Research Results

EPA, eicosapentaenoic acid: Click to Expand ⟱
Features:
Eicosapentaenoic Acid (EPA)
 – An omega-3 polyunsaturated fatty acid (PUFA) primarily found in marine sources such as fatty fish and algae.
 – EPA is involved in the synthesis of eicosanoids, which are signaling molecules that modulate inflammatory processes.

Eicosapentaenoic acid — Eicosapentaenoic acid is a 20-carbon, five-double-bond long-chain omega-3 polyunsaturated fatty acid formally designated 20:5n-3. Its ethyl-ester pharmaceutical form is icosapent ethyl. EPA is obtained mainly from oily fish, marine oils and microalgae, with limited endogenous formation from alpha-linolenic acid. It is a dietary lipid, membrane constituent and precursor of less-inflammatory eicosanoids and specialized pro-resolving mediators. EPA is an approved cardiometabolic drug component but is not an approved anticancer therapy.

Primary mechanisms (ranked):

  1. Remodels membrane phospholipid composition by partly replacing arachidonic acid, thereby altering lipid-raft organization, receptor signalling and the substrate pool available for eicosanoid synthesis.
  2. Shifts lipid-mediator production toward generally less-inflammatory prostaglandins, thromboxanes and leukotrienes and toward E-series resolvins that promote inflammatory resolution.
  3. Suppresses inflammatory signalling, including NF-κB, COX-2, PGE2 and selected cytokines, with effects dependent on tissue, stimulus, EPA dose and treatment duration.
  4. In susceptible cancer cells, increases incorporation of highly peroxidizable omega-3 lipid into membranes, promoting lipid peroxidation, mitochondrial stress, apoptosis and potentially ferroptotic vulnerability.
  5. Modulates PI3K/Akt, MAPK, cell-cycle and apoptosis pathways in experimental cancer models, although the direction and magnitude vary substantially by cancer type and exposure conditions.
  6. May modify tumour-associated inflammation, cachexia-related proteolysis and lipolysis and treatment tolerance; human results are inconsistent and EPA alone has not demonstrated reliable antitumour efficacy.
  7. substantial evidence that EPA can reduce inflammatory signalling, although the effect is strongest in people or cells with pre-existing inflammatory activation.
  8. May enhance chemotherapy or radiotherapy responses in selected experimental models through membrane remodelling and oxidative sensitization, but this remains adjunctive and context-dependent.

Bioavailability / PK relevance: Oral EPA is absorbed with dietary lipid, transported largely through intestinal lymph and incorporated into plasma phospholipids, triglycerides and cholesteryl esters. Icosapent ethyl is hydrolysed during absorption; peak plasma EPA occurs at approximately 5 hours, more than 99% of circulating unesterified EPA is protein-bound, and the reported terminal plasma half-life is approximately 89 hours. Biological effects depend more on sustained membrane incorporation and achieved omega-3 status than on a brief free-plasma concentration. Oxidation, formulation, meal composition and EPA content strongly affect exposure.

In-vitro vs systemic exposure relevance: Many direct anticancer experiments use approximately 25–200 µM EPA for one or more days. These conditions can produce membrane loading and lipid peroxidation greater than ordinary dietary exposure, while less than 1% of circulating EPA is present as unesterified fatty acid. Acute free-EPA concentrations used in vitro therefore commonly exceed physiologically available unbound exposure; longer-term membrane incorporation is the more clinically relevant comparison.

Clinical evidence status: RCT evidence supports prescription icosapent ethyl for selected cardiovascular and hypertriglyceridaemia indications, not cancer treatment. In oncology, evidence consists of preclinical studies, nutritional-intervention trials and small-to-moderate adjunct studies involving cachexia, body composition, inflammatory biomarkers or treatment tolerance. Several controlled cachexia trials were negative or inconclusive, while some nutritional studies reported preservation of weight or lean mass. EPA should be classified as an investigational nutritional adjunct in cancer rather than a demonstrated anticancer agent.

Safety / deployment status: Dietary EPA and conventional fish-oil doses are generally well tolerated, but concentrated prescription EPA can increase bleeding events and atrial fibrillation or flutter, particularly in predisposed patients or those using antiplatelet or anticoagulant drugs. Gastrointestinal effects, fish-derived allergen concerns, product oxidation and variable supplement purity are additional constraints. The FDA-approved icosapent ethyl dose is 4 g/day for its labelled cardiovascular or triglyceride indications; this dose should not be extrapolated as an anticancer regimen.


Mechanistic Effects of EPA

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane phospholipid and arachidonic-acid competition EPA incorporation ↑; arachidonic-acid-derived signalling ↓ EPA incorporation ↑; inflammatory lipid substrate availability ↓ G Membrane remodelling and altered signal transduction Central mechanism requiring sustained exposure; dependent on baseline fatty-acid composition.
2 Eicosanoids and E-series resolvins Pro-inflammatory prostanoid and leukotriene signalling ↓; resolution mediators ↑ Inflammatory resolution ↑; excessive leukocyte activation ↓ R/G Inflammation modulation EPA competes with arachidonic acid and serves as a precursor for less-inflammatory and pro-resolving mediators.
3 NF-κB COX-2 PGE2 cytokine axis NF-κB ↓; COX-2 ↓; PGE2 ↓; IL-6 and TNF signalling ↓ (context-dependent) Stimulus-induced NF-κB and cytokine production ↓ R/G Suppression of inflammatory and tumour-promoting signalling Direction is not universal; some immune contexts show mixed or biphasic regulation.
4 Lipid peroxidation and ferroptotic vulnerability Peroxidizable membrane PUFA ↑; lipid ROS ↑; ferroptotic susceptibility ↑ (model-dependent) Lipid peroxidation ↔ or ↑ when antioxidant capacity is insufficient R/G Oxidative membrane damage in susceptible tumour cells Potential therapeutic leverage but also a stability and normal-tissue constraint; strongly affected by antioxidants and iron availability.
5 Mitochondrial stress and apoptosis Mitochondrial membrane dysfunction ↑; caspase activation ↑; apoptosis ↑ Mitochondrial function ↔ or protected at nutritional exposure; oxidative injury possible at high concentration R/G Programmed cell death Most convincing in cell and animal models using sustained, relatively high EPA exposure.
6 PI3K Akt MAPK and cell-cycle signalling Akt survival signalling ↓; proliferation ↓; cell-cycle arrest ↑ (model-dependent) Stress and metabolic signalling modulation ↔ R/G Reduced proliferation and survival signalling Secondary mechanism with substantial tumour-type and concentration dependence.
7 Cachexia-associated inflammation and catabolism Tumour-derived inflammatory and catabolic signalling ↓ (indirect) Muscle proteolysis ↓; lipolysis ↓; lean-mass preservation ↑ (inconsistent) G Potential nutritional and metabolic support Preclinical rationale is stronger than clinical efficacy; several randomized trials did not show clear benefit.
8 Chemosensitization Drug-induced apoptosis or oxidative injury ↑ (context-dependent) Treatment toxicity ↔ or ↓ in selected nutritional studies G Potential adjunctive treatment modulation Not established as a standard chemosensitizer; effects may differ by drug, tumour genotype and antioxidant environment.
9 Clinical Translation Constraint Direct tumour exposure uncertain; clinical antitumour activity unproven Bleeding risk ↑; atrial fibrillation risk ↑; gastrointestinal intolerance possible G Limits translation from experimental models Formulation, oxidation, meal conditions, baseline omega-3 status, tumour heterogeneity and use of EPA-DHA mixtures complicate interpretation.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Lipid peroxidation and ROS: EPA incorporation increases the abundance of highly peroxidizable membrane polyunsaturated lipids. In susceptible cancer-cell models, EPA increases intracellular ROS and lipid-peroxidation products, contributing to mitochondrial dysfunction, apoptosis or necrosis. The effect is dose-dependent and strongly modified by iron availability, glutathione, glutathione peroxidase activity, vitamin E and other antioxidant defenses. Direct evidence is primarily preclinical and is not consistent across all cancer types.

Membrane EPA incorporation ↑; ROS ↑; lipid peroxidation ↑; apoptosis or necrosis ↑ (dose-dependent) (model-dependent)

Normal cells, Stress-induced ROS ↓; NADPH oxidase activity ↓; basal ROS ↔; lipid peroxidation ↔ or ↑ under strongly pro-oxidant conditions
COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
1085- DHA,  EPA,    DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells
- in-vitro, Nor, HUVECs
*COX2↓, *NF-kB↓, *PGE2↓, *IL6↓, *NF-kB↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL6↓, 1,   NF-kB↓, 1,   NF-kB↑, 1,   PGE2↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:259  Target#:66  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page